GB202302120D0 - Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction - Google Patents
Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunctionInfo
- Publication number
- GB202302120D0 GB202302120D0 GBGB2302120.7A GB202302120A GB202302120D0 GB 202302120 D0 GB202302120 D0 GB 202302120D0 GB 202302120 A GB202302120 A GB 202302120A GB 202302120 D0 GB202302120 D0 GB 202302120D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- diseases
- compounds
- treatment
- conditions associated
- neurodegenerative dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2023/051355 WO2023227881A1 (en) | 2022-05-24 | 2023-05-24 | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2207556.8A GB202207556D0 (en) | 2022-05-24 | 2022-05-24 | Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction |
| GBGB2211273.4A GB202211273D0 (en) | 2022-05-24 | 2022-08-02 | Compounds for use in the treatment of diseases and conditions associated with inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202302120D0 true GB202302120D0 (en) | 2023-03-29 |
| GB2619119A GB2619119A (en) | 2023-11-29 |
Family
ID=82220581
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2207556.8A Ceased GB202207556D0 (en) | 2022-05-24 | 2022-05-24 | Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction |
| GBGB2211273.4A Ceased GB202211273D0 (en) | 2022-05-24 | 2022-08-02 | Compounds for use in the treatment of diseases and conditions associated with inflammation |
| GB2302120.7A Pending GB2619119A (en) | 2022-05-24 | 2023-02-14 | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2207556.8A Ceased GB202207556D0 (en) | 2022-05-24 | 2022-05-24 | Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction |
| GBGB2211273.4A Ceased GB202211273D0 (en) | 2022-05-24 | 2022-08-02 | Compounds for use in the treatment of diseases and conditions associated with inflammation |
Country Status (1)
| Country | Link |
|---|---|
| GB (3) | GB202207556D0 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4344743A2 (en) * | 2018-08-07 | 2024-04-03 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
-
2022
- 2022-05-24 GB GBGB2207556.8A patent/GB202207556D0/en not_active Ceased
- 2022-08-02 GB GBGB2211273.4A patent/GB202211273D0/en not_active Ceased
-
2023
- 2023-02-14 GB GB2302120.7A patent/GB2619119A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2619119A (en) | 2023-11-29 |
| GB202207556D0 (en) | 2022-07-06 |
| GB202211273D0 (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288214A (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| IL288882A (en) | Mixture of plant extracts for use in the prevention and/or treatment of chronic inflammatory bowel diseases | |
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| EP3969125A4 (en) | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases | |
| IL285708A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL288001A (en) | Compounds for the treatment of neurodegenerative and metabolic disorders | |
| EP4054713A4 (en) | Compositions and methods for treatment or prevention of skin diseases and disorders with lekti | |
| EP3913002A4 (en) | Application of ecm1 in prevention and/or treatment of liver fibrosis-related diseases | |
| PT3937948T (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
| GB202302120D0 (en) | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction | |
| GB202211274D0 (en) | Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction | |
| IL290192A (en) | Nitenin analogue compounds and their use in the treatment of chronic and acute pain | |
| EP4087847A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| IL282718A (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| EP4100127A4 (en) | Methods for the treatment of scleroderma and related conditions | |
| GB202217453D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| GB202208255D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| GB202208256D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions |